Orteronel
Orteronel (TAK-700) is a non-steroidal antiandrogen that was being developed for the treatment of cancer by Takeda Pharmaceutical Company in conjunction with Millennium Pharmaceuticals. It completed two phase III clinical trials for metastatic, hormone-refractory prostate cancer but failed to extend overall survival rates, and development was voluntarily terminated as a result.
Orteronel
Orteronel (TAK-700) is a non-steroidal antiandrogen that was being developed for the treatment of cancer by Takeda Pharmaceutical Company in conjunction with Millennium Pharmaceuticals. It completed two phase III clinical trials for metastatic, hormone-refractory prostate cancer but failed to extend overall survival rates, and development was voluntarily terminated as a result.
has abstract
Orteronel (TAK-700) is a non-s ...... lating levels of testosterone.
@en
IUPAC name
6-(7-Hydroxy-6,7-dihydro-5H-py ...... ethylnaphthalene-2-carboxamide
@en
thumbnail
Wikipage page ID
32,684,479
Wikipage revision ID
730,165,196
imagesize
othernames
subject
hypernym
comment
Orteronel (TAK-700) is a non-s ...... tarily terminated as a result.
@en
label
Orteronel
@en
